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Abstract 18 
The present study is aimed to enhance the oral bioavailability of ketoprofen by inserting it into the 19 
matrix of poly(vinylpyrrolidone) (PVP) K10, a water soluble polymer, spatially confined into 20 
microcontainers, by means of supercritical CO2-aided impregnation. Microcontainers are 21 
cylindrical reservoirs, with typical sizes in the micrometer range, with a cavity open on one side, 22 
where the drug formulation is loaded. Differently to traditional tablets, microcontainers have a 23 
higher surface area per unit volume, and release the drug only in one direction. This design is 24 
meant to enhance the absorption of problematic drugs, like those with poor solubility in water. In 25 
a previous study we introduced a novel technique for drug loading of microcontainers, based on 26 
inkjet printing and supercritical impregnation (SCI). We showed that SCI produces accurate and 27 
reproducible drug loading for large arrays of microcontainers. In the attempt of enhancing the 28 
throughput of the loading methods, we propose the replacement of polymer inkjet printing with 29 
an easier manual compression of the PVP powder into the microcontainers. As the second step, 30 
the polymer powder filled-microcontainers were submitted to SCI. The separate role of different 31 
impregnation parameters (temperature, pressure, time, drug concentration in the supercritical 32 
phase) was elucidated with respect to the loading capacity. The microcontainer filling was 33 
observed by means of optical macroimaging, X-ray microtomography and scanning electron 34 
microscopy. The physical state of the drug was investigated by means of Raman spectroscopy and 35 
compared with selected representative PVP-ketoprofen physical mixtures. Finally, the drug loading 36 
was estimated by means of in vitro dissolution tests.  37 
The characterization study shows that the present loading method is a valuable alternative to the 38 
one previously described. The drug loading can be controlled with high accuracy and 39 
reproducibility and the impregnated drug is in amorphous state. These results demonstrate that 40 
SCI can be used as a high throughput  loading technique for microfabricated devices for oral drug 41 
delivery.  42 
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1. Introduction 43 
Among the different drug delivery routes oral administration is still the most preferred one for its 44 
simplicity, minimal invasiveness, and high patient compliance. Nevertheless, the human digestive 45 
system presents a sequence of physiological barriers which drastically reduce the bioavailability of 46 
many active pharmaceutical ingredients (API): enzymatic degradation, hydrolysis in the gastric 47 
acidic environment, thick mucus layer covering the intestinal mucosa, selective transport action of 48 
peptide receptors in the epithelial cells [1]. Such unfavorable conditions are affecting APIs that 49 
exhibit low solubility in water. The solid state properties of drugs have a strong influence on their 50 
solubility. Whilst amorphous drug candidates exhibit an enhanced solubility and dissolution rate 51 
compared to their crystalline counterparts, amorphous forms often suffer from rather short 52 
thermodynamic stability and they spontaneously tend to crystallize [2]. As a result, stabilization of 53 
amorphous forms is necessary in order to preserve the abovementioned advantages [3]. Physical 54 
stabilization of the amorphous form can be achieved by the addition of a polymeric carrier 55 
wherein the drug is confined in supramolecular domains or even molecularly dispersed [4]. 56 
Together with the solid state properties, the solubility and dissolution rate can be improved by 57 
reducing the particle size of the formulation [5]. Among the several formulation approaches [6] 58 
supercritical fluid based technology is a promising technique to produce micro- and 59 
nanoparticulated systems with high drug dispersion and enhanced stability and dissolution 60 
properties [7]. 61 
Beside the properties of the drug formulation, an important role in the therapeutic performance is 62 
often played by the design of the administration form. Conventional oral dosage forms like tablets 63 
provide a omni-directional drug release through their limited interfacial area when exposed to the 64 
physiological fluids. Furthermore, drug release from tablets is often slow compared to the 65 
peristaltic flow in the GI tract, which is the most permeable tissue for drug absorption. As a result, 66 
a large amount of API is not delivered, and patients need to ingest multiple drug doses to receive 67 
the desired therapeutic benefit. This increases the occurrence of potentially harmful side effects in 68 
patients [8]. 69 
In the last 10 years advances in field of micro- and nanofabrication have allowed the development 70 
of alternative drug delivery systems [9]. In particular there has been an increasing interest in 71 
microfabricated devices based on the concept of microcontainers [10] . A microcontainer is a 72 
reservoir with the typical dimensions falling in the micrometer range, composed by a non-73 
permeable and inert shell and a cavity for the drug formulation open on one side from which the 74 
drug is released undirectionally. Several groups developed microcontainers in different shapes, 75 
materials and designs, where fabrication is typically performed on flat silicon chips. By virtue of its 76 
asymmetric shape and by applying appropriate bioadhesive coatings on microcontainers Ainslie et 77 
al. [11] showed an increased intestinal retention time for these microdevices and an enhanced 78 
bioavailability for a model poorly water soluble drug. One of the big challenges in the fabrication 79 
of microcontainers concerns the drug loading step. In a previous work [12], we showed the 80 
fabrication of cylindrical microcontainers, fabricated with the epoxy resin SU-8. The microwells 81 
were filled with poly(vinylpyrrolidone) (PVP) by inkjet printing. This method showed high accuracy 82 
and a minimal waste of materials. In a more recent work [13] we proposed the combination of 83 
inkjet printing and supercritical technology to impregnate the polymer-filled microcontainers with 84 
ketoprofen, a poorly water soluble drug. We demonstrated that the supercritical impregnation 85 
technique allows a highly accurate and reproducible drug loading of large arrays of 86 
microcontainers. In an attempt to enhance the throughput of this loading method, we propose a 87 
simplified variant of our previous work. Here the polymer printing was replaced by an easier filling 88 
method, consisting of a manual compression of the polymer powder onto the microcontainer. 89 
Later, the powder filled-containers were submitted to supercritical impregnation (SCI) as 90 
previously described [13]. This process modification enabled a significant reduction in the sample 91 
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preparation time and made it possible to investigate the effect of temperature, pressure and 92 
impregnation times on different aspects concerning the drug loading in more detail.  93 
The loading procedure was characterized with different techniques. X-ray microtomography was 94 
used to measure the level of filling and the polymer morphology of the polymer powder in the 95 
microreservoir cavities before and after the SCI. In addition, microcontainers were visualized by 96 
scanning electron microscopy (SEM) to observe the effect of the impregnation parameters on the 97 
polymer morphology. Raman spectroscopy was used to investigate the drug solid state in the 98 
impregnated matrices and drug-polymer interactions. Finally, in vitro dissolution tests were 99 
carried out and the total drug loading was estimated. The results showed that the replacement of 100 
inkjet printing with the powder filling method enhances the throughput of the microcontainer 101 
loading technique without compromising the accuracy or the reproducibility of the whole loading 102 
process.  103 
2. Materials and methods  104 
2.1 Fabrication of SU-8 microcontainers 105 
2.1.1 Materials and fabrication of microcontainers 106 
Silicon wafers (4-inch b100N n-type) were supplied by Okmetic (Vantaa, Finland). SU-8 2075 and 107 
SU-8 developer were purchased from Microresist Technology GmbH (Berlin, Germany).  108 
Cylindrical microcontainers were fabricated with a similar procedure as previously described [12]. 109 
The microwells were fabricated with the epoxy-based photoresist SU-8 on silicon wafers arranged 110 
in a squared chip containing an array of 25x25 microcontainers. A microcontainer has a cavity of 111 
approximately 300 µm in diameter and 270 µm in depth and an approximated volume of 18 nL. 112 
After the fabrication the wafer was cut into square chips containing 625 microcontainers (DISCO 113 
DAD 321, Automatic Dicing Saw). 114 
2.2 Drug loading of microcontainers  115 
2.2.1 Materials  116 
Ketoprofen (98%, racemate) and polyvinylpyrrolidone (PVP K10, Mw 10,000) were supplied by 117 
Sigma Aldrich. Carbon dioxide was supplied by SIAD (99% purity). Ketoprofen is a nonsteroidal 118 
anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. In several 119 
pharmacopoeias ketoprofen is considered as practically insoluble in water [14]. Its solubility in 120 
pure water at room temperature (22-24°C) was reported to be 0.010 mg/mL [15]. Thus, 121 
ketoprofen is classified as a class II active principle in the biopharmaceutical classification system 122 
(BCS): It exhibits low aqueous solubility and a high intestinal permeability.  123 
 124 
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Figure 1: Chemical structure of (a) ketoprofen, (b) monomer of poly (vinyl 
pyrrolidone) (PVP).  
(a) (b)
Q 
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2.2.2 Filling with poly(vinylpyrrolidone) PVP powder 131 
Microcontainers were filled with PVP powder with the following procedure: the powder was 132 
deposited and compacted with a spatula onto the microwells and the residual amount, placed in 133 
between containers, was blown away by means of a pressurized air. The chip was weighed before 134 
and after filling and the average PVP weight per chip was estimated. The level of microcontainer 135 
filling was measured by X-ray microtomography in different positions of the chip. 136 
2.2.3 Supercritical impregnation of polymer filled-microcontainers 137 
After the powder deposition the drug was loaded into the polymer-filled microdevices by means 138 
of supercritical carbon dioxide impregnation. Figure 1.2 depicts a schematic of the high pressure 139 
setup used in the impregnation experiments. The operation was performed in a 100 mL reactor 140 
(KM 20-05 autoclave NWA, Germany) equipped with a magnetic stirrer drive (Mrk MINI 100) 141 
assembled in a sealed housing directly threading into the reactor head. During the impregnation 142 
experiments the reactor was fed with liquid CO2 through an on/off valve (V1) by a high pressure 143 
pump (PM-101NWA, NWA, Germany). At the end of the experiments the reactor was slowly 144 
emptied through an on/off purge valve followed by a lamination valve (V2) and the outlet stream 145 
was connected to a deflux flask were the gaseous CO2 was bubbled through an ethanol solution 146 
(95%) and the ketoprofen concentration was measured. The resulting drug solution was made up 147 
to defined volumes and the drug content was estimated by UV spectroscopy measurements 148 
(Thermo Scientific Evolution 60 - Thermo Fisher Scientific Inc.). Finally, the drug free-CO2 stream 149 
was connected to a flowmeter (SIM Brunt, Italy). 150 
 
Figure 2: Schematic of the high pressure plant. Fi and Vi indicate 0.5 µm filters and on/off valves. 
 151 
The impregnation experiments were carried out in batch conditions with defined steady-state 152 
values of CO2 pressure, temperature and stirring velocity. In each batch, weighted amounts of 153 
crystalline ketoprofen powder and one chip were placed in separate compartments of a sample 154 
carrier placed at the bottom of the reactor. In order to avoid damage to the microcontainers 155 
during the chamber filling with the supercritical fluid, the back of the chips were glued onto the 156 
sample carrier with a carbon pad tape. The reactor was then sealed and heated to the defined 157 
temperature. When the set point temperature was achieved, the inlet valve was gradually opened 158 
and the chamber was slowly filled with CO2, in order to maintain isothermal conditions and avoid 159 
turbulence within the reactor, which could result in detachment of the chip and damaging of the 160 
microcontainers. When the desired pressure was achieved, the inlet valve was closed and the 161 
stirrer was switched on. During the experiment the supercritical CO2 phase dissolved the solid drug 162 
powder and swelled the polymer within the microcontainers. The drug was therefore physically 163 
Reactor
(with magnetic stirrer
and electric heating)
CO2
F1
Pump
V1
F2
V2
Lamination
valve
Water 
saturator
Wet Gas
meter
T probe P transducer
5 
 
conveyed and loaded in the polymer matrices. The impregnations were carried out at a fluid 164 
pressure of 100 and 200 bar, temperatures of 40, 50 and 60°C and durations of 1 and 4 hours with 165 
a stirring velocity of 20 rpm, respectively. 166 
In the experiments run at 100 bar the drug was dissolved under saturation conditions according to 167 
the solubility values of ketoprofen in supercritical CO2 reported by Macnaughton et al. [16] at the 168 
chosen conditions of temperature. In this group of experiments the temperature and time were 169 
modified from batch to batch. Because of the batch conditions, the drug concentration could not 170 
be kept at solubility value over time. In contrast, in the tests performed at 200 bar a fixed amount 171 
of ketoprofen was dissolved, corresponding to the saturation concentration of the compound at 172 
200 bar and 40°C. At 200 bar and 50°C and 60°C the amount of drug was dissolved under 173 
saturation conditions, as the solubility values are higher at these temperatures. In the experiment 174 
performed at 200 bar, the exclusive effect of temperature and time on the microcontainer 175 
impregnation was studied. At the end of the experiment the reactor was depressurized at a 176 
controlled rate for approximately 2 and 3 hours when the operating pressures were 100 and 200 177 
bar respectively. After the experiments the chips were stored in a desiccator until further analysis 178 
were performed. In Table 1 the operating conditions of the experiments are shown. 179 
 180 
Table 1: Mass of ketoprofen [mg] dissolved in the different experimental conditions 181 
Pressure [bar] 
Temperature [°C] 
40 50 60 
100 4.83 2.15 1.31 
200 14.1 14.1 14.1 
 182 
2.3 Characterization methods 183 
2.3.1 X-ray microtomography (XμCT) 184 
For the XμCT measurements a Skyscan 1172/F instrument (Skyscan, Kontich, Belgium, control 185 
software v1.5.13) was used. A source voltage of 60 kV and current of 165 μA were used together 186 
with a 0.5 mm thick Al filter to attenuate the high energy X-rays. For each sample 780 shadow 187 
images were acquired over 180 of rotation. The resulting data acquisition time was 4 h for each 188 
sample. Reconstruction of the cross-section images was performed using the program 189 
NRecon+GPUReconServer (Skyscan, beta v1.6.5) on a single PC using GPU accelerated 190 
reconstruction (Windows 7 64-bit workstation, 2 Intel Xeon X5647 with 4 cores each, 48 GB RAM, 191 
NVIDIA quadro 4000 with 256 cores). Image reconstruction using the Feldkamp algorithm [17] for 192 
cone beam geometry took about 30 min per sample and resulted in, depending on sample size, 193 
about 1450 slices of 2864 x 2876 pixels each (5.2 μm isotropic voxel size). Using the DataViewer 194 
(Skycan, v1.4.4) the tablet was rotated to align the microwells parallel to the x-axis. 195 
 196 
2.3.2 Scanning electron microscopy (SEM)  197 
The morphology of the impregnated microcontainers was examined using SEM. The investigations 198 
were carried out using a Nova600 NanoSEM from FEI (Eindhoven, the Netherlands). Imaging was 199 
performed in low-vacuum-mode at a pressure of 0.6 mbar and an operation voltage of 5 kV. Prior 200 
to examination, the samples were mounted onto metal stubs and were tilted by approx. 30 201 
degrees. 202 
 203 
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2.3.3 Raman spectroscopy 204 
As described in a previous study [13], Raman spectroscopy can be used to elucidate the presence 205 
of chemical interactions amongst drug molecules and between drug and polymer. The spectra 206 
from the impregnated microcontainers were collected using a Thermo Scientific Raman DXR 207 
microscope equipped with a frequency-stabilized single mode diode laser. The Raman signal 208 
collection time was 5 sec and the signal was averaged three times, using a 25 µm slit and a 1.0 µm 209 
diameter laser post. The Raman DXR microscope was coupled to a single grating spectrometer 210 
with a 5 cm-1 FWHM spectral resolution and a ±2 cm-1 wavenumber accuracy. All Raman spectra 211 
were recorded at a laser power of 10 mW, using a 10X objective lens and a laser excitation 212 
wavelength of 780 nm. In each sample 5 containers, located at different positions on the chip, 213 
were selected and analyzed. The intrinsic fluorescence background was fitted to a polynomial 214 
function and subtracted from the collected signal. 215 
2.3.4 In vitro drug dissolution studies 216 
Dissolution of PVP and ketoprofen from loaded microcontainers was determined in 10 ml DI water 217 
at 37˚ C using a UV spectrophotometer μDISS profiler (Pion, USA). Individual chips were glued with 218 
carbon pads on teflon-coated magnets which stirred at 100 rpm. For the detection of ketoprofen, 219 
the wavelength was set to 259 nm. After dissolution, the microcontainers were observed with an 220 
optical microscope (Zeiss, Germany, 10x magnitude) to confirm complete emptying. The amount 221 
of drug loaded per chip was estimated by the final concentration measured in the dissolution test 222 
at 16 hours. Solubility of ketoprofen at 37 °C in aqueous solutions changes significantly with pH 223 
between 1 and 7 [14]. Nevertheless, even in the test with the highest drug loading, the pH of the 224 
dissolution medium drop below 6.5 as ketoprofen is a weak acid (pKa 4.5). Therefore, according to 225 
solubility data reported in the literature [14], the dissolution tests were performed in conditions 226 
below saturation that is without drug precipitation, which was also confirmed by the non-227 
decreasing monotonic trend of the drug dissolution profiles (data not shown).  228 
3. Results and discussion 229 
3.1 Polymer filling of microcontainers and X-ray microtomography 230 
A picture of arrays of microcontainers filled with PVP powder is shown in Figure 3. The powder 231 
filling required few seconds to be performed and resulted in an accurate deposition inside the 232 
cylindrical cavities of the microwells, with minimal residues in between, as representatively 233 
illustrated by the high color contrast between the dark silicon surface and the brilliant white of 234 
PVP powder. In Figure 4 a scanning electron microscopy image of microcontainers filled with PVP 235 
powder is reported. The polymer granules are compacted inside the microwells and this 236 
confinement prevents them from being removed by the air flow which is used to remove the loose 237 
powder after the filling step.. Figure 5 shows the cross-sections that were reconstructed from the 238 
microtomography data of the XμCT measurements. Using this technique it is possible to measure 239 
the internal microstructure of the PVP powder within the containers and to visualise the effect of 240 
the impregnation on the particle morphology. The images clearly show that the microcontainers 241 
are filled with discrete PVP particles before impregnation and subsequently coalesce following 242 
treatment with supercritical CO2. 243 
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Figure 3: Optical macro images of microcontainers filled with PVP powder by manual compaction: 
(a) detail of the chip corner, (b) arrays in the middle of the chip. 
 
 
Figure 4: SEM images of microcontainers filled with polyvinylpyrrolidone before treatment with 
supercritical CO2. The scalebar indicates 300 µm. 
 244 
 
 
 
 
 
Figure 5: Non-destructive cross-sections acquired by XμCT through the microcontainers filled 
with polyvinylpyrrolidone before treatment with supercritical CO2 (a) and after impregnation (b). 
The original grey scale images are shown together with a binary threshold image to highlight the 
change in polymer morphology. 
 245 
(a) 
(b) 
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3.2 Scanning Electron Microscopy of impregnated microcontainers 246 
After the supercritical treatment, the microcontainers were analyzed by scanning electron 247 
microscopy to observe the effects of the impregnation on the polymer morphology. As shown in a 248 
previously [13], the SEM micrographs (see Figure 6) confirm that scCO2 does not visible effects on 249 
the epoxy resin used to fabricate the microcontainers (SU-8) which maintain their size, the 250 
cylindrical shape and the adhesion to the silicon substrate. The supercritical fluid has instead a 251 
much more pronounced effect on PVP. At all the tested conditions, the morphology of PVP 252 
radically changes as the polymer particles undergo swelling and subsequent coalescence as 253 
confirmed by the XµCT images (Figure 5b). By comparing the SEM micrographs of microcontainers 254 
treated at different pressures it is clear that the volume of the polymer visibly increases with 255 
increasing CO2 pressure. This can be explained by an increase of CO2 uptake in PVP with pressure, 256 
in accordance with what was previously reported by Kikic and co-workers [18]. At high pressures, 257 
CO2 has a well-known plasticizing effect on certain polymers [19,20]. The plasticization leads to a 258 
drop in the Tg, which for PVP K10 is around 87 ˚C, a temperature close to the operating 259 
temperature during impregnation. As a result, the polymer gets close to the glass-rubber 260 
transition. The increase of impregnation time in general leads to a higher extent of swelling of the 261 
matrix and to the appearance of holes. At 40 ˚C and 50 ˚C these holes got larger when the pressure 262 
was set at 200 bar, and this fact can be attributed to the release of CO2 from the highly swollen 263 
matrices. At 200 bar and 50 ˚C small spots appear on the polymer surface. At 200 bar and 60 ˚C 264 
these particles clustered in bigger aggregates (see Figures 6(k) and 6(l)) on small number of 265 
containers in the chip. As scCO2 acts as a plasticizer for polymers the viscosity of the CO2 saturated 266 
matrix decreases during impregnation [34] causing spillages, in some cases, from the containers. 267 
This aspect is more pronounced during longer experiments. 268 
 269 
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Figure 6: Scanning electron microscopy images of polymer filled microcontainers impregnated 
with ketoprofen by supercritical CO2 at different pressure, temperature and time. The scalebar 
indicates 300 µm.  
 270 
3.3 Loading of ketoprofen into polymer filled-microcontainers 271 
The solubility of ketoprofen in scCO2 monotonically increases with the fluid density, and therefore 272 
with the fluid pressure at isothermal conditions [16]. Furthermore, for many active compounds 273 
under isobaric conditions the temperature influences the solubility according to the operating 274 
pressure and with respect to the crossover pressures. At the crossover points solubility isotherms 275 
overturn their trend [16]. The upper crossover pressure of ketoprofen in carbon dioxide was 276 
measured between 160 and 180 bar [18,21]. Below this pressure, such as at 100 bar, the drug 277 
solubility decreases with temperature. At higher pressures, such as at 200 bar, the effect of 278 
temperature is the opposite. The impregnation pressures were chosen on different positions 279 
towards the upper crossover point in order to explore the behavior of the supercritical phase on 280 
the drug loading. In figure 7 the resulting weight fraction of ketoprofen (keto) loaded in a chip 281 
containing 625 PVP filled-microcontainers is compared for the different impregnation conditions. 282 
Despite the simplicity of the method the overall accuracy of the loading is similar to the one 283 
previously reported where the polymer was deposited by inkjet printing [12].  284 
In the tests carried out at 100 bar (Figure 7a) the drug was dissolved in saturation conditions. Here 285 
the loading is strongly dependent on the drug concentration in the supercritical phase, which was 286 
higher at 40˚C and lower at 60˚C. There is an increase in drug loading over time for any tested 287 
temperature meaning that after 1 hour the equilibrium is not yet attained. After 4 hours the drug 288 
weight fraction is approximately doubled at all temperatures. To investigate the partition 289 
equilibrium of the drug between the CO2 and the polymer phases an impregnation experiment 290 
was carried out at 40˚C for 24 hours. The attained drug fraction was 0.27, which is very close to 291 
the loading achieved after 4 hours. In the experiments at 200 bar, the impregnation is enhanced 292 
compared to experiments at 100 bar as a result of the combined effect of the higher amount of 293 
drug dissolved (see table 1) and the density of the fluid at this pressure. However, at 200 bar the 294 
loading increased with the temperature which was unexpected, since at this pressure a rise of 295 
temperature leads to an increase of drug solubility and therefore a less favorable drug partition in 296 
the polymer matrix. Moreover, from 40 ˚C to 60 ˚C the fluid density decreases as shown in the 297 
profiles in Figure 8, where the loaded API weights are plotted as a function of the CO2 density. 298 
These latter results can be explained by considering that the effect of temperature on drug-scCO2 299 
diffusivity prevails over the reduced fluid density. A temperature increase also results in  enhanced 300 
mobility of the polymer chains, which is suggested by the visible swelling observed in Figures 6(d), 301 
6(h) and 6(l). In contrast to the results at 100 bar, at 200 bar more limited loading gains for 302 
impregnation time were achieved. This might be due to the proximity of the drug concentration in 303 
the polymer to the saturation, which can slow down the impregnation process. 304 
 305 
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Figure 7: Mass fraction of ketoprofen (keto) impregnated in polymer filled 625 microcontainers at 
different temperatures and times: (a) at 100 bar in saturation conditions (b) at 200 bar with a fixed 
amount of drug dissolved in scCO2(N=3). 
 306 
 
Figure 8: Mass of ketoprofen impregnated at 200 bar in 625 microcontainers at different 
temperatures and times (N=3) as function of the CO2 density. 
 307 
Table 2: Drug loading of impregnated microcontainers. The drug weight refers to total loaded 308 
mass on individual chips (625 microcontainers) and is normalized with respect to the polymer 309 
mass in the microwells (N = 3). 310 
T( C) P(bar) Time (h) Loaded drug per 
chip (mg) 
Drug weight fraction 
(keto/(PVP+keto)) 
40 
100 
1 0.33 ± 0.09 0.15 ±0.03 
4 0.58 ± 0.02 0.26 ±0.02 
200 
1 0.53 ± 0.07 0.23 ±0.03 
4 0.58 ± 0.01 0.27 ±0.03 
50 
100 
1 0.19 ± 0.02 0.10 ±0.01 
4 0.40 ± 0.04 0.18 ±0.02 
200 
1 0.55 ± 0.03 0.26 ±0.01 
4 0.71 ± 0.04 0.27 ±0.03 
60 
100 
1 0.08 ± 0.03 0.04 ±0.01 
4 0.16 ± 0.04 0.06 ±0.01 
200 
1 0.77 ± 0.06 0.26 ±0.03 
4 1.05 ± 0.03 0.33 ±0.01 
 311 
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3.4 Raman spectroscopy 312 
Another important aspect for a drug delivery device is the API solid state properties and the 313 
stabilization of the amorphous phase in a polymer matrix. For this purpose, Raman scattering 314 
spectroscopy was utilized to detect the presence of amorphous ketoprofen and the molecular 315 
interactions with the polymer. In order to elucidate the presence of drug-polymer interactions, 316 
additional Raman spectra were collected from microcontainers filled with physical mixtures (PMs) 317 
of the polymer and drug. Raman scattering spectra of both fresh ketoprofen:PVP PMs and 318 
mixtures prepared by supercritical CO2 are shown in Figure 9. In the ketoprofen:PVP PM case, the 319 
Raman scattering spectra from both compounds are added together and retain all characteristics 320 
of isolated ketoprofen and PVP, see Figure 9(a). To illustrate this, the inter-ring ketoprofen 321 
carbonyl [C=O] stretching mode [22] found at 1657 cm-1 is examined for different drug/PVP ratios. 322 
In all cases the Raman intensity of the ketoprofen C=O stretching mode compared to the 1602 cm-323 
1 C-C stretching mode is I1657/I1602 > 1. The Raman vibration can be fitted to two Lorentzian 324 
functions outlining modes that belong to both ketoprofen and PVP. The FWHM of the C=O 325 
stretching mode is similar to the one recorded for pure ketoprofen shown in the bottom part of 326 
Figure 9(a). The PM result indicates no observable intermolecular interaction between the two 327 
compounds [13]. The 1657 cm-1 Raman mode for supercritical CO2 impregnated ketoprofen:PVP 328 
mixtures behaves differently, i.e. the vibrational mode intensity is reduced and the FWHM is 329 
significantly increased, see Figure 9(b). In this case, the two Lorentzian fits yield essentially a single 330 
Raman peak without a clear contribution from PVP and I1657/I1602 < 1 almost for all drug/PVP 331 
ratios. Since there is no observable frequency shift, the result suggests that this carbonyl group is 332 
not involved in the formation of hydrogen bonds with PVP molecules. The recorded change rather 333 
indicates rearrangement of ketoprofen molecules into a less organized solid state, and a similar 334 
effect was previously observed for aged ketoprofen:PVP PM mixtures [13]. The presence of 335 
amorphous ketoprofen was previously confirmed by X-ray diffraction [13]. It is also expected that 336 
the CO2 assisted impregnation of PVP with ketoprofen breaks or reduces the interaction between 337 
adjacent ketoprofen molecules and induces the formation of the hydrogen bonds between oxydryl 338 
groups of ketoprofen molecules and carbonyl groups of PVP [23].  339 
 340 
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Figure 9: Raman spectra of (a) physical mixtures of PVP and crystalline ketoprofen in different 
representative weight percentages and (b) spectra of PVP impregnated with the same 
ketoprofen weight percentages at different experimental conditions (see table 2). 
 341 
4. Conclusions 342 
The present study investigates the use of CO2-aided impregnation to load ketoprofen into 343 
microcontainers filled with PVP by tuning temperature, pressure, time, and drug concentration in 344 
the fluid phase. The characterization study shows that drug loading can be controlled with high 345 
accuracy and reproducibility and the impregnated drug is in the amorphous state. At any tested 346 
pressure there is an increase of drug loading over time for any tested temperature meaning that 347 
after 1 hour the equilibrium between the polymer and the CO2 phases is not yet attained. From 348 
the tests at 100 bar it was observed that the loading is strongly dependent on the drug 349 
concentration in the impregnating medium. Unexpectedly, in the tests at 200 bar the loading 350 
increased with the temperature despite the increasing drug solubility in the scCO2. This was 351 
attributed to the predominance of drug diffusivity in the polymer matrix. In contrast, at 200 bar 352 
more limited loading gains for increasing impregnation time were obtained probably due to the 353 
proximity of drug saturation in the polymer. The Raman scattering spectra of the impregnated 354 
matrices indicate a rearrangement of ketoprofen molecules into a less organized state. However, 355 
no observable frequency shift  in was noticed for the spectral modes typically ascribed to drug-356 
polymer interactions, which suggests that the drug molecule is unlikely to be involved in the 357 
formation of hydrogen bonds with PVP molecules.  358 
Our results demonstrate that the combination of powder loading and SCI can be used as a high 359 
throughput loading technique for microfabricated devices for oral drug delivery. 360 
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